119 related articles for article (PubMed ID: 33461945)
21. Feasibility and safety of 1.5 T MR-guided and daily adapted abdominal-pelvic SBRT for elderly cancer patients: geriatric assessment tools and preliminary patient-reported outcomes.
Mazzola R; Figlia V; Rigo M; Cuccia F; Ricchetti F; Giaj-Levra N; Nicosia L; Vitale C; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Alongi F
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2379-2397. PubMed ID: 32372146
[TBL] [Abstract][Full Text] [Related]
22. Stereotactic body radiotherapy in patients with hepatocellular carcinoma in a multimodal treatment setting.
Gerum S; Heinz C; Belka C; Walter F; Paprottka PM; De Toni EN; Roeder F
Strahlenther Onkol; 2020 Apr; 196(4):334-348. PubMed ID: 31732784
[TBL] [Abstract][Full Text] [Related]
23. The role of albumin-bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy.
Gkika E; Bettinger D; Krafft L; Schultheiss M; Neeff HP; Maruschke L; Schulenburg M; Adebahr S; Kirste S; Nestle U; Thimme R; Grosu AL; Brunner TB
Strahlenther Onkol; 2018 May; 194(5):403-413. PubMed ID: 29322205
[TBL] [Abstract][Full Text] [Related]
24. Thermal Ablation Versus Stereotactic Body Radiotherapy After Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis.
Nabavizadeh N; Jahangiri Y; Rahmani R; Tomozawa Y; Geeratikun Y; Chen Y; Hung A; Degnin C; Farsad K
AJR Am J Roentgenol; 2021 Sep; 217(3):691-698. PubMed ID: 32997517
[No Abstract] [Full Text] [Related]
25. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
[TBL] [Abstract][Full Text] [Related]
26. Stereotactic body radiotherapy versus hepatic resection for hepatocellular carcinoma (≤ 5 cm): a propensity score analysis.
Sun J; Wang Q; Hong ZX; Li WG; He WP; Zhang T; Zhang AM; Fan YZ; Sun YZ; Zheng L; Duan XZ
Hepatol Int; 2020 Sep; 14(5):788-797. PubMed ID: 32886334
[TBL] [Abstract][Full Text] [Related]
27. Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis.
Shui Y; Yu W; Ren X; Guo Y; Xu J; Ma T; Zhang B; Wu J; Li Q; Hu Q; Shen L; Bai X; Liang T; Wei Q
Radiat Oncol; 2018 Sep; 13(1):188. PubMed ID: 30253783
[TBL] [Abstract][Full Text] [Related]
28. Stereotactic body radiation therapy for centrally located hepatocellular carcinoma: outcomes and toxicities.
Lazarev S; Hardy-Abeloos C; Factor O; Rosenzweig K; Buckstein M
J Cancer Res Clin Oncol; 2018 Oct; 144(10):2077-2083. PubMed ID: 30088143
[TBL] [Abstract][Full Text] [Related]
29. Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases.
Andratschke N; Parys A; Stadtfeld S; Wurster S; Huttenlocher S; Imhoff D; Yildirim M; Rades D; Rödel CM; Dunst J; Hildebrandt G; Blanck O
Radiat Oncol; 2016 May; 11():74. PubMed ID: 27236333
[TBL] [Abstract][Full Text] [Related]
30. Predictive factors for survival following stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumour thrombosis and construction of a nomogram.
Li X; Ye Z; Lin S; Pang H
BMC Cancer; 2021 Jun; 21(1):701. PubMed ID: 34126955
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients.
Lee S; Jung J; Park JH; Kim SY; Choi J; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Park HH; Kim JH; Yoon SM
BMC Cancer; 2022 Feb; 22(1):175. PubMed ID: 35172769
[TBL] [Abstract][Full Text] [Related]
32. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Tse RV; Hawkins M; Lockwood G; Kim JJ; Cummings B; Knox J; Sherman M; Dawson LA
J Clin Oncol; 2008 Feb; 26(4):657-64. PubMed ID: 18172187
[TBL] [Abstract][Full Text] [Related]
33. Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT).
Murray LJ; Sykes J; Brierley J; Kim JJ; Wong RKS; Ringash J; Craig T; Velec M; Lindsay P; Knox JJ; Dawson LA
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):900-909. PubMed ID: 29976502
[TBL] [Abstract][Full Text] [Related]
34. A mid-treatment break and reassessment maintains tumor control and reduces toxicity in patients with hepatocellular carcinoma treated with stereotactic body radiation therapy.
Jackson WC; Suresh K; Maurino C; Feng M; Cuneo KC; Ten Haken RK; Lawrence TS; Schipper MJ; Owen D
Radiother Oncol; 2019 Dec; 141():101-107. PubMed ID: 31431377
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcomes of stereotactic body radiation therapy for small hepatocellular carcinoma.
Park S; Jung J; Cho B; Kim SY; Yun SC; Lim YS; Lee HC; Park J; Park JH; Kim JH; Yoon SM
J Gastroenterol Hepatol; 2020 Nov; 35(11):1953-1959. PubMed ID: 32052884
[TBL] [Abstract][Full Text] [Related]
36. Stereotactic body radiation therapy for early hepatocellular carcinoma: a retrospective analysis of the South Australian experience.
Wigg AJ; Narayana SK; Le H; Iankov I; Chinnaratha MA; Tse E; Chen JW; Gowda R
ANZ J Surg; 2019 Sep; 89(9):1138-1143. PubMed ID: 30983104
[TBL] [Abstract][Full Text] [Related]
37. Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma.
Gkika E; Schultheiss M; Bettinger D; Maruschke L; Neeff HP; Schulenburg M; Adebahr S; Kirste S; Nestle U; Thimme R; Grosu AL; Brunner TB
Radiat Oncol; 2017 Jul; 12(1):116. PubMed ID: 28701219
[TBL] [Abstract][Full Text] [Related]
38. Impact of stereotactic body radiation therapy on geriatric assessment and management for older patients with head and neck cancer using G8.
Gogineni E; Rana Z; Wotman M; Karten J; Riegel A; Marrero M; Maduro L; Kamdar D; Frank D; Paul D; Seetharamu N; Ghaly M
J Geriatr Oncol; 2021 Jan; 12(1):122-127. PubMed ID: 32593669
[TBL] [Abstract][Full Text] [Related]
39. Feasibility of marker-less stereotactic body radiotherapy for hepatocellular carcinoma.
Kibe Y; Takeda A; Tsurugai Y; Eriguchi T; Oku Y; Kimura Y; Nakamura N
Acta Oncol; 2022 Jan; 61(1):104-110. PubMed ID: 34788194
[TBL] [Abstract][Full Text] [Related]
40. Response criteria in solid tumors (PERCIST/RECIST) and SUV
Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
